N/A
Completed N=32
Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Toxicities
Source: ClinicalTrials.gov NCT01015326 ↗
Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcomePrimary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale
Summary
Epidermal Growth Factor Receptor Inhibitors (EGFRI) are associated with skin toxicities. Clinical experience suggests that skin toxicities interfere with health related quality of life (HRQL) and may interfere with treatment adherence. No systematic investigations of EGFRI-associated dermatologic toxicities and impact on HRQL have been reported. No patient-reported outcome measures exist to capture the unique concerns of oncology patients who experience EGFRI-associated dermatologic toxicities.
The purpose of this study is to develop a patient-reported outcomes measure to assess dermatologic-related symptoms burden and health-related quality of life among patients receiving an EGFRI, and to develop a grading system for EGFRI-associated dermatologic toxicities.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) |
2.70; 2.41; 2.70; 2.29; 1.90; 2.14 | — |
Eligibility Criteria
Inclusion Criteria
- Undergoing anti-EGFR cancer therapy
- Over 18 years old
Exclusion Criteria
- Unable to complete the questionnaire
- Unable to follow instructions or give consent
Data sourced from ClinicalTrials.gov (NCT01015326). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.